Lundbeck Valuation Multiples

Lundbeck Overview

About Lundbeck

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

Founded

1915

HQ

Employees

5.3K

Website

lundbeck.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $4B

EBITDA: $1B

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Lundbeck Financials

Lundbeck reported last 12-month revenue of $4B and EBITDA of $1B.

In the same LTM period, Lundbeck generated $3B in gross profit, $1B in EBITDA, and $537M in net income.

Lundbeck P&L

In the most recent fiscal year, Lundbeck reported revenue of $4B and EBITDA of $1B.

Lundbeck expects next 12-month revenue of XXX and NTM EBITDA of XXX

Lundbeck Stock Performance

Lundbeck has current market cap of $6B, and enterprise value of $7B.

Lundbeck's stock price is $5.84.

Lundbeck Valuation Multiples

Lundbeck trades at 1.8x EV/Revenue multiple, and 6.1x EV/EBITDA.

Lundbeck Financial Valuation Multiples

As of March 21, 2026, Lundbeck has market cap of $6B and EV of $7B.

Equity research analysts estimate Lundbeck's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lundbeck has a P/E ratio of 10.8x.

Lundbeck Margins & Growth Rates

Lundbeck's revenue in the last 12 month grew by 1%.

Lundbeck's revenue per employee in the last FY averaged $0.7M.

Lundbeck's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lundbeck's rule of X is 31% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Lundbeck Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Lundbeck M&A Activity

Lundbeck acquired XXX companies to date.

Last acquisition by Lundbeck was on XXXXXXXX, XXXXX. Lundbeck acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Lundbeck Investment Activity

Lundbeck invested in XXX companies to date.

Lundbeck made its latest investment on XXXXXXXX, XXXXX. Lundbeck invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).